OSSO, a promising Delhi-based startup revolutionizing orthopaedics through regenerative and non-surgical approaches, has closed a INR 4 crore seed round led by the Haldiram family office. The funding, announced January 6, 2026, also includes notable angels, marking strong validation for its “next-gen orthopaedics” model.

OSSO (One Stop Shop For Orthopaedics) addresses musculoskeletal (MSK) issues like joint pain, sports injuries, arthritis, and degenerative conditions via integrated clinics blending physiotherapy, regenerative therapies (e.g., PRP, stem cell), diagnostics, and personalized rehab. By emphasizing non-invasive options, it reduces surgery needs while improving recovery speed and long-term mobility.

Founders Avani Agarwal and Kunal Kishore Dhawan drawing from personal experiences with ortho challenges aim to create accessible, outcome-focused care. “When Avani and I started OSSO, our aim was simple: create an environment where folks experiencing any kind of musculoskeletal problem get world-class care,” Dhawan shared on LinkedIn.

The fresh capital will accelerate centre expansions (currently focused in Delhi-NCR), tech enhancements for patient tracking/tele-rehab, and clinical R&D. This follows a $250K pre-seed in March 2025 from investors including Sahil Jindal (DS Jindal Group) and Umesh Agarwal (Haldiram family office) indicating continued support from early backers.

Haldiram family office’s lead underscores growing family office interest in health-tech, particularly solutions tackling lifestyle-driven ortho issues in India’s young population.

OSSO positions itself in a high-growth segment: India’s orthopaedics market is booming with rising sports participation, ageing demographics, and awareness of regenerative alternatives to surgery.